Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?

Mirghani H, Lacroix L, Rossoni C, Sun R, Aupérin A, Casiraghi O, Villepelet A, Lacave R, Faucher G, Marty V, Ferté C, Soria JC, Even C.

Eur J Cancer. 2018 May;94:61-69. doi: 10.1016/j.ejca.2018.02.013. Epub 2018 Mar 20.

PMID:
29533868
2.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
3.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: Eur J Cancer. 2018 Feb 14;:.

PMID:
29145038
4.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
5.

[Computational medical imaging (radiomics) and potential for immuno-oncology].

Sun R, Limkin EJ, Dercle L, Reuzé S, Zacharaki EI, Chargari C, Schernberg A, Dirand AS, Alexis A, Paragios N, Deutsch É, Ferté C, Robert C.

Cancer Radiother. 2017 Oct;21(6-7):648-654. doi: 10.1016/j.canrad.2017.07.035. Epub 2017 Aug 31. Review. French.

PMID:
28865968
6.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C.

Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.

PMID:
28826073
7.

Evaluation of 16 commercial antibody ELISAs for the detection of bovine viral diarrhea virus-specific antibodies in serum and milk using well-characterized sample panels.

Hanon JB, De Baere M, De la Ferté C, Roelandt S, Van der Stede Y, Cay B.

J Vet Diagn Invest. 2017 Nov;29(6):833-843. doi: 10.1177/1040638717724839. Epub 2017 Aug 14.

PMID:
28803517
8.

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence.

Dercle L, Ammari S, Bateson M, Durand PB, Haspinger E, Massard C, Jaudet C, Varga A, Deutsch E, Soria JC, Ferté C.

Sci Rep. 2017 Aug 11;7(1):7952. doi: 10.1038/s41598-017-08310-5.

9.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
10.

Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.

Ou D, Blanchard P, Rosellini S, Levy A, Nguyen F, Leijenaar RTH, Garberis I, Gorphe P, Bidault F, Ferté C, Robert C, Casiraghi O, Scoazec JY, Lambin P, Temam S, Deutsch E, Tao Y.

Oral Oncol. 2017 Aug;71:150-155. doi: 10.1016/j.oraloncology.2017.06.015. Epub 2017 Jun 26.

PMID:
28688683
11.

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Ferté C.

Eur J Cancer. 2017 Aug;81:161-173. doi: 10.1016/j.ejca.2017.05.006. Epub 2017 Jun 17. Review.

PMID:
28628842
12.

The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.

Clémenson C, Chargari C, Liu W, Mondini M, Ferté C, Burbridge MF, Cattan V, Jacquet-Bescond A, Deutsch E.

Mol Cancer Ther. 2017 Oct;16(10):2107-2119. doi: 10.1158/1535-7163.MCT-17-0112. Epub 2017 Jun 15.

PMID:
28619752
13.

A step towards the harmonization of clinical trials inform consent forms.

Remon J, Ferté C.

Ann Oncol. 2017 May 1;28(5):910-912. doi: 10.1093/annonc/mdx082. No abstract available.

PMID:
28453709
14.

iRECIST: A clarification of tumour response assessment in the immunotherapy era.

Ferté C, Marabelle A.

Eur J Cancer. 2017 May;77:165-167. doi: 10.1016/j.ejca.2017.02.015. Epub 2017 Apr 4. No abstract available.

PMID:
28385325
15.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

PMID:
28365644
16.

Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology.

Limkin EJ, Sun R, Dercle L, Zacharaki EI, Robert C, Reuzé S, Schernberg A, Paragios N, Deutsch E, Ferté C.

Ann Oncol. 2017 Jun 1;28(6):1191-1206. doi: 10.1093/annonc/mdx034. Review.

PMID:
28168275
17.

Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma.

Gorphe P, Matias M, Even C, Ferte C, Bidault F, Garcia G, Temam S, Nguyen F, Blanchard P, Tao Y, Janot F.

Anticancer Res. 2016 Dec;36(12):6625-6630.

PMID:
27919993
18.

Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy.

Gorphe P, Matias M, Blanchard P, Even C, Ferte C, Tao Y, Temam S, Bidault F, Janot F.

Laryngoscope. 2017 Aug;127(8):1791-1796. doi: 10.1002/lary.26425. Epub 2016 Nov 26.

PMID:
27888508
19.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C.

Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.

20.

In Regard to Mattonen et al.

Sun R, Orlhac F, Robert C, Reuzé S, Schernberg A, Buvat I, Deutsch E, Ferté C.

Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1544-1545. doi: 10.1016/j.ijrobp.2016.03.038. No abstract available.

PMID:
27479727
21.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S.

Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21.

PMID:
27451022
22.

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T.

Eur J Cancer. 2016 May;59:79-89. doi: 10.1016/j.ejca.2016.02.006. Epub 2016 Mar 24.

PMID:
27017289
23.

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L.

Clin Cancer Res. 2016 Jun 15;22(12):2960-8. doi: 10.1158/1078-0432.CCR-15-2470. Epub 2016 Jan 12.

24.

rCGH: a comprehensive array-based genomic profile platform for precision medicine.

Commo F, Guinney J, Ferté C, Bot B, Lefebvre C, Soria JC, André F.

Bioinformatics. 2016 May 1;32(9):1402-4. doi: 10.1093/bioinformatics/btv718. Epub 2015 Dec 26.

25.

TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen.

Marquard AM, Birkbak NJ, Thomas CE, Favero F, Krzystanek M, Lefebvre C, Ferté C, Jamal-Hanjani M, Wilson GA, Shafi S, Swanton C, André F, Szallasi Z, Eklund AC.

BMC Med Genomics. 2015 Oct 1;8:58. doi: 10.1186/s12920-015-0130-0.

26.

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

Hollebecque A, Malka D, Ferté C, Ducreux M, Boige V.

Eur J Cancer. 2015 Feb;51(3):327-39. doi: 10.1016/j.ejca.2014.12.005. Epub 2015 Jan 2. Review.

PMID:
25559615
27.

Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology.

Commo F, Ferté C, Soria JC, Friend SH, André F, Guinney J.

Ann Oncol. 2015 Mar;26(3):582-8. doi: 10.1093/annonc/mdu582. Epub 2014 Dec 23.

28.

Social interactomes for enabling research communities.

Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F.

Cancer Discov. 2014 Nov;4(11):1265-8. doi: 10.1158/2159-8290.CD-14-0774.

29.

Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.).

Verlingue L, Koscielny S, Ferté C.

Eur J Cancer. 2014 Nov;50(16):2887-8. doi: 10.1016/j.ejca.2014.07.026. Epub 2014 Sep 15. No abstract available.

PMID:
25218336
30.

TGR analysis in phase I clinical trials--response.

Ferté C, Koscielny S, Soria JC.

Clin Cancer Res. 2014 May 1;20(9):2497. doi: 10.1158/1078-0432.CCR-14-0366. No abstract available.

31.

Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC.

Oncoimmunology. 2014 Jan 1;3(1):e27817. Epub 2014 Jan 16.

32.

[Management of the cardiovascular complications of treatment in thoracic oncology].

Ederhy S, Hollebecque A, Haddour N, Massard C, Fleury G, Ferte C, Adavane S, Besse B, Boccara F, Soria JC, Cohen A.

Rev Mal Respir. 2014 Feb;31(2):173-80. doi: 10.1016/j.rmr.2013.09.021. Epub 2014 Jan 31. Review. French.

PMID:
24602684
33.

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C, Ammari S, Soria JC.

Clin Cancer Res. 2014 Jan 1;20(1):246-52. doi: 10.1158/1078-0432.CCR-13-2098. Epub 2013 Nov 15.

34.

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.

Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang KM, Bendtsen C, Hudson K, Huang E, Dougherty B, Ducreux M, Soria JC, Friend S, Derry J, Laurent-Puig P.

Clin Cancer Res. 2014 Jan 1;20(1):265-272. doi: 10.1158/1078-0432.CCR-13-1943. Epub 2013 Oct 29.

35.

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.

Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B.

Eur Urol. 2014 Apr;65(4):713-20. doi: 10.1016/j.eururo.2013.08.010. Epub 2013 Aug 15.

PMID:
23993162
36.

Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology.

Ferté C, Trister AD, Huang E, Bot BM, Guinney J, Commo F, Sieberts S, André F, Besse B, Soria JC, Friend SH.

Clin Cancer Res. 2013 Aug 15;19(16):4315-25. doi: 10.1158/1078-0432.CCR-12-3937. Epub 2013 Jun 18. Review.

37.

IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.

Ferté C, Loriot Y, Clémenson C, Commo F, Gombos A, Bibault JE, Fumagalli I, Hamama S, Auger N, Lahon B, Chargari C, Calderaro J, Soria JC, Deutsch E.

Mol Cancer Ther. 2013 Jul;12(7):1213-22. doi: 10.1158/1535-7163.MCT-12-1067. Epub 2013 May 2.

38.

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review.

Bibault JE, Fumagalli I, Ferté C, Chargari C, Soria JC, Deutsch E.

Cancer Metastasis Rev. 2013 Dec;32(3-4):479-92. doi: 10.1007/s10555-013-9419-7. Review.

PMID:
23595306
39.

Predictive value of clinical judgment of tumour progression in phase II trials.

Kotecki N, Penel N, Adenis A, Ferte C, Clisant S.

PLoS One. 2012;7(12):e52638. doi: 10.1371/journal.pone.0052638. Epub 2012 Dec 26.

40.

Tumor assessment criteria in phase I trials: beyond RECIST.

Levy A, Hollebecque A, Ferté C, Koscielny S, Fernandez M, Soria JC, Massard C.

J Clin Oncol. 2013 Jan 20;31(3):395. doi: 10.1200/JCO.2012.46.2184. Epub 2012 Dec 17. No abstract available.

PMID:
23248247
41.

Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?

Ferté C, Massard C, Cohen A, Soria JC, Ederhy S.

Am J Clin Oncol. 2012 Apr;35(2):183-4. doi: 10.1097/COC.0b013e318214e01f. No abstract available.

PMID:
22433996
42.

FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.

Ferte C, Romano O, Mariette C, Bourgeois V, Peugniez C, Lindet C, Ladrat L, Triboulet JP, Hebbar M.

J Chemother. 2011 Dec;23(6):358-61.

PMID:
22233821
43.

Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models.

Ploquin A, Olmos D, Ferté C, Cassier PA, Kramar A, Duhamel A, Penel N.

Crit Rev Oncol Hematol. 2012 Aug;83(2):242-8. doi: 10.1016/j.critrevonc.2011.11.008. Epub 2012 Jan 9. Review.

PMID:
22226569
44.

Tumour growth rates and RECIST criteria in early drug development.

Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC.

Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15.

PMID:
21763126
45.

[Pharmacological targeting of Mdm2: rationale and perspectives for radiosensitization].

Chargari C, Leteur C, Ferté C, Deberne M, Lahon B, Rivera C, Bourhis J, Deutsch E.

Cancer Radiother. 2011 Jul;15(4):316-22. doi: 10.1016/j.canrad.2011.02.003. Epub 2011 Jun 23. Review. French.

PMID:
21684790
46.

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

Ferté C, Paci A, Zizi M, Gonzales DB, Goubar A, Gomez-Roca C, Massard C, Sahmoud T, André F, Soria JC.

Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017. Epub 2011 Apr 12.

PMID:
21489779
47.

Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.

Ferte C, Soria JC, Penel N.

PLoS One. 2011 Mar 2;6(3):e16633. doi: 10.1371/journal.pone.0016633.

48.

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

Ferté C, André F, Soria JC.

Nat Rev Clin Oncol. 2010 Jul;7(7):367-80. doi: 10.1038/nrclinonc.2010.84. Epub 2010 Jun 15. Review.

PMID:
20551944
49.

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.

Ferté C, Besse B, Dansin E, Parent F, Buisine MP, Copin MC, Penel N, Soria JC.

Ann Oncol. 2010 Jun;21(6):1385-7. doi: 10.1093/annonc/mdq153. Review. No abstract available.

PMID:
20501506
50.

Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary.

Ferté C, Penel N, Bonneterre J, Adenis A.

Oncology. 2010;78(2):87-93. doi: 10.1159/000306137. Epub 2010 Mar 30. Review.

PMID:
20357516

Supplemental Content

Support Center